Nationwide survey on acute heart failure in cardiology ward services in Italy.

AIMS Chronic heart failure (HF) is recognized as an important public health problem but little attention has been focused on acute-stage HF. METHODS AND RESULTS Nationwide, prospective, observational study setting 206 cardiology centres with intensive cardiac care units. During 3 months, 2807 patients diagnosed as having de novo acute HF (44%) or worsening chronic HF (56%) were enrolled. Acute pulmonary oedema was the presenting clinical feature in 49.6% of patients, cardiogenic shock in 7.7%, and worsened NYHA functional class in 42.7% of cases. Anaemia (Hb<12 g/dL) was present in 46% of patients, renal dysfunction (creatinine > or =1.5 mg%) in 47%, and hyponatraemia (< or =136 mEq/L) in 45%. An ejection fraction (EF)>40% was found in 34% of cases. Intravenous diuretics, nitrates, and inotropes were given to 95, 51, and 25% of patients, respectively. The median duration of hospital stay was 9 days. In-hospital mortality rate was 7.3%. Older age, use of inotropic drugs, elevated troponin, hyponatraemia, anaemia, and elevated blood urea nitrogen were independent predictors of all-cause death; prior revascularization procedures and elevated blood pressure were indicators of a better outcome. The rehospitalization rate within 6 months was 38.1%, all-cause mortality from discharge to 6 months was 12.8%. CONCLUSION Acute HF is an ominous condition, needing more research activity and resources.

[1]  Paula Finn,et al.  American Heart Association--scientific sessions 2005. 13-16 November 2005, Dallas, TX, USA. , 2006, IDrugs : the investigational drugs journal.

[2]  R. Goldberg,et al.  Incidence and hospital death rates associated with heart failure: a community-wide perspective. , 2005, The American journal of medicine.

[3]  M. Nieminen,et al.  Acute heart failure: Clinical presentation, one‐year mortality and prognostic factors , 2005, European journal of heart failure.

[4]  Dario Gregori,et al.  Temporal trends in survival and hospitalizations in outpatients with chronic systolic heart failure in 1995 and 1999. , 2005, Journal of cardiac failure.

[5]  V. Hasselblad,et al.  Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. , 2005, Journal of cardiac failure.

[6]  K. Adams,et al.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.

[7]  K. Dickstein,et al.  [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]. , 2005, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[8]  L. Tavazzi,et al.  Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n‐3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure , 2004, European journal of heart failure.

[9]  V. Hasselblad,et al.  Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 trial). , 2004, The American journal of cardiology.

[10]  N. Freemantle,et al.  Clinical trials update and cumulative meta‐analyses from the American College of Cardiology: WATCH, SCD‐HeFT, DINAMIT, CASINO, INSPIRE, STRATUS‐US, RIO‐Lipids and cardiac resynchronisation therapy in heart failure , 2004, European journal of heart failure.

[11]  Peter C Austin,et al.  Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. , 2003, JAMA.

[12]  L. Tavazzi,et al.  Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worlds--the TEMISTOCLE study. , 2003, American heart journal.

[13]  N. Freemantle,et al.  The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. , 2003, European heart journal.

[14]  N. Freemantle,et al.  The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment , 2003 .

[15]  N Freemantle,et al.  The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. , 2003, European heart journal.

[16]  L. Tavazzi,et al.  Treatment of chronic heart failure with β adrenergic blockade beyond controlled clinical trials: the BRING-UP experience , 2003, Heart.

[17]  C. O'connor,et al.  The problem of decompensated heart failure: nomenclature, classification, and risk stratification. , 2003, American heart journal.

[18]  M. Gheorghiade,et al.  Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization. , 2003, American heart journal.

[19]  T. LeJemtel,et al.  Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. , 2002, American heart journal.

[20]  J. Cleland,et al.  Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial , 2002, The Lancet.

[21]  Z. Vered,et al.  Acute heart failure: a novel approach to its pathogenesis and treatment , 2002, European journal of heart failure.

[22]  E. Perna,et al.  Cardiac troponin T levels are associated with poor short- and long-term prognosis in patients with acute cardiogenic pulmonary edema. , 2002, American heart journal.

[23]  K. Swedberg,et al.  Comprehensive guidelines for the diagnosis and treatment of chronic heart failure Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology , 2002, European journal of heart failure.

[24]  J. Papp,et al.  STEERING COMMITTEE AND INVESTIGATORS OF THE LEVOSIMENDAN INFUSION VERSUS DOBUTAMINE (LIDO) STUDY. EFFICACY AND SAFETY OF INTRAVENOUS LEVOSIMENDAN COMPARED WITH DOBUTAMINE IN SEVERE LOWOUTPUT HEART FAILURE (THE LIDO STUDY): A RANDOMISED DOUBLEBLIND TRIAL , 2002 .

[25]  K. Swedberg,et al.  Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.

[26]  K. Kataoka,et al.  Persistently Increased Serum Concentrations of Cardiac Troponin T in Patients With Idiopathic Dilated Cardiomyopathy Are Predictive of Adverse Outcomes , 2001, Circulation.

[27]  D. Rubin,et al.  Small-sample degrees of freedom with multiple imputation , 1999 .

[28]  J. Croft,et al.  Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. , 1999, American heart journal.

[29]  Y. Moshkovitz,et al.  Increased toxicity of high‐dose furosemide versus low‐dose dopamine in the treatment of refractory congestive heart failure , 1997, Clinical pharmacology and therapeutics.

[30]  M. Condorelli,et al.  Inotropic stimulation by dobutamine increases left ventricular regional function at the expense of metabolism in hibernating myocardium. , 1996, American heart journal.